India's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
India's Zydus Lifesciences posts lower profit as expenses outpace revenue growth Nov 4 (Reuters) - Indian drugmaker Zydus Lifesciences ZYDU.NS reported a 26.6% fall in second-quarter profit on Wednesday, as rising expenses outweighed stronger demand, pushing its shares about 4% lower.
Consolidated net profit fell to 9.26 billion rupees ($97.77 million) for the July-September quarter from 12.61 billion rupees a year earlier.
Here are more details:
Total revenue rose 29.2% year-on-year to 79.10 billion but expenses grew at a faster pace of 51%, including a 36.4% increase in R&D and 33.7% increase in employee benefits expenses
Revenue from North America, Zydus' largest market, rose 20.8% to 33.15 billion rupees, aided by higher volumes and new launches for generic drugs
Revenue from India, its second-largest market, grew 18%, driven by its chronic disease portfolio
Analysts at Motilal Oswal said growth in Zydus' domestic business in the second quarter was helped by market share gains in chronic, acute therapies, and differentiated launches
Larger rival Dr Reddy's REDY.NS reported a better-than-expected quarterly profit, as domestic demand offset competitive pressures in the US market, while Cipla CIPL.NS missed profit estimates on weakness in its key North American market
($1 = 94.7100 Indian rupees)
(Reporting by Puyaan Singh in Bengaluru; Editing by Sonia Cheema)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka